Ultrafast 30‐min infusion of a rituximab biosimilar (Truxima)

Ultrafast 30‐min infusion of a rituximab biosimilar (Truxima)

Abstract In this clinical trial, we demonstrate that ultrarapid fast infusion of rituximab (Truxima) in 30 min with oral premedication is feasible and secure for patients, and reduce the day‐care hospital stays.

Bibliographic Details
Main Authors: Ernesto Pérez‐Persona, Laida Cuevas Palomares, Ariane Unamunzaga Cilaurren, Xabier Gutiérrez López de Ocáriz, Buenaventura Buendía Ureña, Ana Vega González de Viñaspre, Begoña Benito Ibarrondo, María Carmen Molinillo Fernández, Ana Cordero Osúa, Beatriz Benítez Delgado, Juan José García Albás, Miguel Ángel Andrés Moralejo, José María Guinea de Castro
Format: Article
Language:English
Published: Wiley 2023-11-01
Series:eJHaem
Subjects:
rituximab
ultrafast infusion
cost‐efective
Online Access:https://doi.org/10.1002/jha2.812

Internet

https://doi.org/10.1002/jha2.812

Similar Items